Treatment of Patients With Myelofibrosis and Uncontrolled Polycythemia Vera
EHA Learning Center. Novartis D. Aug 23, 2017; 193789
Topic: Section 2: Clinical hematology myeloid malignancies
Delivered by Novartis
Delivered by Novartis
Login now to access Regular content available to all registered users.

Access to EHA Members only content is an EHA membership benefit.
Click here to join EHA or renew your membership here.

Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
- To determine if patients with early myelofibrosis would benefit from treatment
- To understand the management options for patients with cytopenias on JAK-inhibitor treatment
- To discuss which patients with MF are usually considered for allogeneic stem cell transplant
- To be able to identify uncontrolled polycythemia vera (PV) and discuss which drugs are appropriate options for secondline cytoreduction"
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings